Login to Your Account



‘Room for Some Pricing Leverage’

Keryx’s Zerenex Phase II Wows; Expanded CKD Sales in Reach?

By Randy Osborne
Staff Writer

Tuesday, November 5, 2013
Keryx Biopharmaceuticals Inc.’s Zerenex (ferric citrate) may be poised to become the first oral iron booster that also provides phosphorous control in chronic kidney disease (CKD) patients, if new top-line data from a Phase II trial hold up.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription